Kalshi and Polymarket push into drug and TV betting amid insider-trading and tax warnings
Kalshi and Polymarket are expanding into new contract categories even as regulatory and compliance risks intensify. Kalshi now offers wagers on cancer drug trials and is exploring clinical trial outcomes. Polymarket commands the dominant share of political prediction market volume. Both platforms face mounting scrutiny: the CFTC has warned against gambling-style marketing, young Washington staffers with non-public information are trading on the platforms, and a Reuters commentary warns that gamification could invite Tobin-style transaction taxes. Prediction markets have also drawn millions in bets on reality TV outcomes.
The CFTC's branding crackdown already forces Kalshi and Polymarket to strip gambling vocabulary from marketing. That raises user acquisition costs just as Novig's $125 million opening week is grabbing market share. The platforms' expansion into drug trials and reality TV adds fresh attack surfaces. Drug approval contracts risk perverse incentives around trial data and medical research integrity.
The Reuters tax warning means Congress now has a revenue argument if it moves to impose Tobin-style levies on event-contract trading. Insider trading by Washington staffers gives enforcement hawks a concrete abuse case to cite. Each new contract category multiplies the regulatory exposure. A platform that missteps on promotional language or contract design gives Congress, the NFL, and state attorneys general fresh ammunition for bans or restrictions. Rivals watch for any CFTC escalation beyond warnings to formal charges.